Showing results (1-10 of 54) with videos related to
Sort By:
Pageof 6
World Journal of Gastrointestinal Oncology|August 7, 2013
Chemotherapy for cholangiocarcinoma: An updateNatalia Ramírez-Merino, Santiago Ponce Aix, Hernán Cortés-FunesStudies in Health Technology and Informatics|April 9, 2025
Data-Driven Assessment of Lung Cancer Patients Using Performance Status and Wearable Device MetricsIoannis Bilionis, Luis Fernandez Luque, Santiago Ponce Aix, et al.JTO Clinical and Research Reports|January 13, 2022
Prognostic Value of Clinical Staging According to TNM in Patients With SCLC: A Real-World Surveillance Epidemiology and End-Results Database AnalysisEdurne Arriola, José Manuel Trigo, Amparo Sánchez-Gastaldo, et al.Frontiers in Medicine|April 21, 2017
Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of DacomitinibJon Zugazagoitia, Asunción Díaz, Elisabeth Jimenez, et al.JCO Clinical Cancer Informatics|November 3, 2023
Data-Driven Personalized Care in Lung Cancer: Scoping Review and Clinical Recommendations on Performance Status and Activity Level of Patients With Lung Cancer Using Wearable DevicesSantiago Ponce Aix, Francisco J Núñez-Benjumea, Sergio Cervera-Torres, et al.Plos One|March 17, 2015
Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)Susana Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia, et al.Journal of B.U.ON. : Official Journal of the Balkan Union of Oncology|July 14, 2018
Clinical impact of gastric acid suppressing medication on the effectiveness of tyrosine kinase inhibitors in lung cancer patientsMarcos Nieves Sedano, José Manuel Caro Teller, Carmen García Muñoz, et al.Journal of Experimental & Clinical Cancer Research : CR|August 19, 2018
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinomaIrene Ferrer, Álvaro Quintanal-Villalonga, Sonia Molina-Pinelo, et al.Scientific Reports|February 7, 2018
The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin InductionÁlvaro Quintanal-Villalonga, Laura Ojeda-Márquez, Ángela Marrugal, et al.Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
FGFR4 increases EGFR oncogenic signaling in lung adenocarcinoma, and their combined inhibition is highly effectiveAlvaro Quintanal-Villalonga, Sonia Molina-Pinelo, Patricia Yagüe, et al.Pageof 6